13 recruiting, 8 active not recruiting, 4 not yet recruiting. 25 Phase 3, 8 Phase 2.
By phase and status
Follow Iza-bren: new trials by email Literature Review of Iza-bren trials Research Report on Iza-bren
Trials (filtered) newest first · largest first
All 25 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06) BL-B01D1, PD-1/VEGF Bispecific Antibody, Tislelizumab - Non-squamous Non-small Cell Lung Cancer Phase 2 / Phase 3 Not yet recruiting 166 2026-11-01 2026-10-28 Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) Iza-bren, Osimertinib, Pemetrexed - Non-Small Cell Lung Cancer Phase 3 Recruiting 850 2026-09-08 2026-11-10 A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04) BL-B01D1, PD-1 monoclonal antibody, Nab-paclitaxel - Triple-Negative Breast Cancer (TNBC) Phase 3 Recruiting 436 2026-09-02 2026-09-30 A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02) BL-B01D1, PD-1 monoclonal antibody, cisplatin - Nasopharyngeal Carcinoma (NPC) Phase 3 Not yet recruiting 404 2026-09-01 2026-09-15 A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer BL-B01D1, Abiraterone, Olaparib - Castration-resistant Prostate Cancer Phase 2 / Phase 3 Not yet recruiting 180 2026-09-01 2026-07-23 A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08) BL-B01D1, Osimertinib - Non-small Cell Lung Cancer Stage III Phase 3 Recruiting 418 2026-08-28 2026-09-10 A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) BL-B01D1, PD-1/VEGF bispecific antibody, Paclitaxel - Squamous Non-small-cell Lung Cancer Phase 2 / Phase 3 Not yet recruiting 200 2026-08-01 2026-08-26 A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) BL-B01D1, Osimertinib, Carboplatin - Non-small Cell Lung Cancer Phase 2 / Phase 3 Recruiting 90 2026-07-24 2026-08-03 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) BL-B01D1, Albumin-Bound Paclitaxel, Paclitaxel - Breast Cancer Phase 3 Recruiting 446 2026-07-06 2026-07-23 A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01) BL-B01D1, Oxaliplatin, Calcium levofolinate - Biliary Tract Cancer Phase 3 Recruiting 538 2026-06-29 2026-07-24 A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) BL-B01D1, Tislelizumab, Carboplatin - Extensive-stage Small-cell Lung Cancer Phase 3 Recruiting 562 2026-06-15 2026-10-28 A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) BL-B01D1, Tislelizumab, 5-Fluorouracil - Esophageal Squamous Cell Carcinoma Phase 2 / Phase 3 Recruiting 90 2026-06-09 2026-07-16 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) Iza-bren, Carboplatin, Cisplatin - Non-Small Cell Lung Cancer Phase 2 / Phase 3 Recruiting 500 2025-11-05 2026-10-09 Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy Iza-bren, Cisplatin, Gemcitabine - Urothelial Cancer Phase 2 / Phase 3 Recruiting 470 2025-09-30 2026-07-29 A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) Iza-bren, Nab-paclitaxel, Paclitaxel - Breast Neoplasms Phase 2 / Phase 3 Recruiting 600 2025-09-11 2026-08-10 A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan - Epithelial Ovarian Cancer, Fallopian Tube Cancer Phase 3 Recruiting 450 2025-08-04 2026-07-07 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) BL-B01D1, Docetaxel or Paclitaxel - Urothelial Carcinoma Phase 3 Active not recruiting 515 2025-03-25 2026-10-21 A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04) BL-B01D1, Osimertinib - Non-small Cell Lung Cancer Phase 3 Recruiting 720 2025-02-24 2026-04-20 A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) BL-B01D1, Topotecan - Small Cell Lung Cancer Phase 3 Active not recruiting 722 2024-08-07 2026-04-17 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) BL-B01D1, Eribulin, Vinorelbine - Triple-Negative Breast Cancer Phase 3 Active not recruiting 418 2024-06-21 2026-07-23
Showing 20 of 25. Sign in to see all of them.
Conditions studied Carcinoma, Non-Small-Cell Lung (7) · Triple Negative Breast Neoplasms (3) · Breast Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Nasopharyngeal Carcinoma (2) · Small Cell Lung Carcinoma (2) · Biliary Tract Neoplasms (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Transitional Cell (1) · Fallopian Tube Neoplasms (1) · Lung Neoplasms (1) · Urinary Bladder Neoplasms (1)
Sponsors Sichuan Baili Pharmaceutical Co., Ltd. (21) · Bristol-Myers Squibb (4)
Countries China (25) · Argentina (4) · Canada (4) · France (4) · Germany (4) · Italy (4) · Japan (4) · Spain (4) · United States (4) · Australia (3) · Brazil (3) · India (3) · Romania (3) · South Korea (3) · Switzerland (3)
Top investigators Li Zhang, PHD (2) · Binghe Xu (1) · Jian Zhang (1) · Jie Wang (1) · Jiong Wu (1) · Li Zhang (1) · Lin Shen, PHD (1)
Results publications PMID 41125110 , PMID 42497381